Login to Your Account



Immunomedics moves key pancreatic cancer drug into phase III

By Marie Powers
Staff Writer

Friday, January 10, 2014
in_the_clinic.jpg

Immunomedics Inc. took a major step forward in its late-stage pipeline with the launch of the Phase III registration study of its pancreatic cancer drug, yttrium-90 (90Y)-clivatuzumab tetraxetan.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription